LONDON, UK / ACCESSWIRE / October 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Auris Medical Holding AG (NASDAQ: EARS) ("Auris Medical"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=EARS. The Company announced on October 11, 2017, that it has executed two share purchase agreements with Lincoln Park Capital Fund, LLC ("LPC") for up to $15 million. For immediate access to our complimentary reports, including today's coverage, register for free now at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on EARS. Go directly to your stock of interest and access today's free coverage at:
On October 10, 2017, Auris Medical also signed a separate purchase agreement with LPC, pursuant to which LPC subscribed for $1.5 million worth of Auris Medical's common shares.
Terms of the Agreement
- In accordance with the purchase agreement dated October 10, 2017, Auris Medical may require LPC from time to time to subscribe for up to $13.5 million worth of its common shares. It is at the sole discretion of LPC.
- Auris Medical will file a registration statement covering the common shares that may be issued to LPC under the purchase agreement, with the Securities and Exchange Commission (SEC).
- Pursuant to the purchase agreement, share subscriptions may take place over the 30-month period after the registration statement is declared effective by the SEC.
- Auris Medical will control the timing of any future investment by LPC. The subscription price of the common shares will be based on the prevailing market prices of the Company's shares at the time of each issuance to LPC.
Share Purchase Agreement Will Help in Extending Auris Medical's Financial Runway
Thomas Meyer, Founder, Chairman, and Chief Executive Officer of Auris Medical, stated that the Company welcomes LPC as a new shareholder and appreciate its investment as Auris Medical approaches key milestones for its three current clinical-stage development programs. The share purchase agreements provide great flexibility and the potential to extend the Company's financial runway well beyond these important milestones.
Auris Medical Announces Transfer to Nasdaq Capital Market
On September 28, 2017, Auris Medical announced the approval of the Company's request to the Nasdaq Stock Market LLC, to transfer the listing of its common shares to the Nasdaq Capital Market from the Nasdaq Global Market. The Company's shares would continue to trade uninterrupted under the symbol "EARS." Additionally, Nasdaq granted the Company an additional 180-day grace period to regain compliance with Nasdaq's minimum bid price requirement.
About Auris Medical Holding AG (NASDAQ: EARS)
Founded in 1998, Auris Medical is a Swiss biopharmaceutical Company dedicated to developing therapeutics that address important unmet medical needs in otology. The Company is dedicated to developing novel pharmaceutical therapies to protect hearing and to silence tinnitus and is the leading pioneer in the emerging field of cochlear (inner ear) therapies. Auris Medical is headquartered in Zug, Switzerland.
About Lincoln Park Capital Fund, LLC
LPC is a Chicago-based Investment Group and Asset Management Firm focused on investing in public and private companies, real estate, and money management strategies.
Last Close Stock Review
On Thursday, October 12, 2017, the stock closed the trading session at $0.87, dropping 5.01% from its previous closing price of $0.91. A total volume of 491.60 thousand shares have exchanged hands, which was higher than the 3-month average volume of 312.16 thousand shares. Auris Medical's stock price surged 20.45% in the last one month and 15.47% in the previous six months. The stock currently has a market cap of $27.59 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily